VICP Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 geg. 2024 @ 17:31):

Stats
Dzisiejszy wolumen	1 245.00
Średni wolumen	81.00
Kapitalizacja rynkowa	31.75M
EPS	$-0.00699 ( 2023-09-29 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-33.00
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2010-09-03	Yurkowski Michael	Sell	5 000	SSGI
2010-08-09	Yurkowski Michael	Sell	20 000	Common Stock
2010-05-13	Moore Bobby M Jr	Sell	0	Common Stock
2010-01-26	Yurkowski Michael	Sell	5 000	SSGI
2010-01-14	Yurkowski Michael	Sell	5 000	Common Stock

INSIDER POWER
0.00
Last 19 transactions
Buy: 0 \| Sell: 1 754 181

Vicapsys Life Sciences, Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Vicapsys Life Sciences, Finanse

Annual	2022
Przychody:	$0
Zysk brutto:	$-31 288.00 (0.00 %)
EPS:	$-0.0545

FY	2022
Przychody:	$0
Zysk brutto:	$-31 288.00 (0.00 %)
EPS:	$-0.0545

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-0.0100

FY	2020
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-0.100

Financial Reports:

No articles found.

Vicapsys Life Sciences,

Vicapsys Life Sciences, Inc. focuses on the development and commercialization of VICAPSYN proprietary product. Its product is applied to transplantation therapies and related stem-cell applications in the transplantation field. The company is also developing VYBRIN, a product based on CXCL12 for prevention of post-surgical adhesions in abdominal surgery, coating of implantable medical devices and other implants to eliminate fibrosis, and wound healing with a focus on diabetic ulcers. The company was formerly known as Phage Therapeutics International, Inc. and changed its name to Vicapsys Life Sciences, Inc. in September 2017. Vicapsys Life Sciences, Inc. was incorporated in 1997 and is based in Suwanee, Georgia.